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Background: Prevalence of multidrug resistant tuberculosis (MDR-TB), defined as in vitro resistance to both
rifampicin and isoniazid with or without resistance to other TB drugs, in sub-Saharan Africa (SSA) is reportedly low
compared to other regions. These estimates are based on data reported to the World Health Organization (WHO)
on drug resistance surveys, which may suffer from a reporting bias. We set out to evaluate the variation in prevalence
of drug resistant tuberculosis (DR-TB) and its determinants across SSA countries among new and previously treated TB
patients.
Methods: The aim was to perform a systematic review and meta-analysis of DR-TB prevalence and associated risk
factors in SSA. PubMed, EMBASE, Cochrane and bibliographies of DR-TB studies were searched. Surveys at
national or sub-national level, with reported DR-TB prevalence (or sufficient data to calculate a prevalence) to
isoniazid (INH), rifampicin (RMP), ethambutol (EMB), and streptomycin (SM) conducted in SSA excluding the
Republic of South Africa, published between 2003 and 2013 with no language restriction were considered.
Two authors searched and reviewed the studies for eligibility and extracted the data in pre-defined forms.
Forest plots of all prevalence estimates by resistance outcome were performed. Summary estimates were
calculated using random effects models, when appropriate. Associations between any DR-TB and MDR-TB
with potential risk factors were examined through subgroup analyses stratified by new and previously treated
patients.
Results: A total of 726 studies were identified, of which 27 articles fulfilled the inclusion criteria. Studies
reported drug susceptibility testing (DST) results for a total of 13,465 new and 1,776 previously treated TB
patients. Pooled estimate of any DR-TB prevalence among the new cases was 12.6% (95% CI 10.6-15.0) while
for MDR-TB this was 1.5% (95% CI 1.0-2.3). Among previously treated patients, these were 27.2% (95% CI 21.4-33.8)
and 10.3% (95% CI 5.8-17.4%), respectively. DR-TB (any and MDR-TB) did not vary significantly with respect to study
characteristics.
Conclusions: The reported prevalence of DR-TB in SSA is low compared to WHO estimates. MDR-TB in this
region does not seem to be driven by the high HIV prevalence rates.
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Globally, the World Health Organization (WHO) re-
ports an estimated prevalence of 3.6% and 20.2% among
notified TB cases for primary and acquired multidrug re-
sistant tuberculosis (MDR-TB), respectively, with signifi-
cant country and regional variations [1]. Despite the high
burden of TB in sub-Saharan Africa (SSA) fuelled by HIV
[1], drug resistance surveillance has not been widely done,
with only 22 of the 46 countries reporting drug resistance
data by 2005. These studies have been designed to estab-
lish a nationwide MDR-TB prevalence only, and most of
them had small sample sizes to assess variations between
subpopulations or identify potential risk factors of the
prevalence of drug resistance [2]. Yet, the use of inferior
TB drug regimens, high HIV infection rates, and a wide
roll-out of ART may predispose countries in this region to
high levels of drug resistant tuberculosis (DR-TB) [3]. In
particular, previous exposure to anti-TB treatment is a
well-established risk factor for DR-TB [4]. By 2010, a
number of TB programs in SSA were still using the eight-
months regimen of two months of ethambutol (EMB), iso-
niazid (INH), rifampicin (RMP), and pyrazinamide (PZA),
followed by six months of EMB and INH. This regimen
has been associated with lower cure rates and higher rates
of relapse than the currently recommended six-months
regimen in which rifampicin is given throughout treat-
ment (two months of EMB,INH,RMP,PZA followed by
four months of RMP and INH) [4]. Conversely, dur-
ation of RMP treatment beyond four months has been as-
sociated with increased risk of acquiring drug resistance
in initially drug sensitive strains [5]. Additionally, there
have been concerns that, in SSA, six months of directly
observed therapy are often unfeasible, and RMP through-
out would increase the incidence of MDR-TB, in particu-
lar in the context of high HIV prevalence and pre-existing
INH resistance [6]. While some drug resistance studies
have shown an association between HIV and DR-TB/
MDR, data showing HIV as an independent risk factor for
MDR-TB in individuals have been limited to particular
settings [7]. Nevertheless, high mortality among HIV pa-
tients suffering from MDR or extensively drug-resistant
tuberculosis (XDR: defined as resistance to any of the
fluoroquinolones (such as ofloxacin or moxifloxacin) and
to any of the three injectable second-line anti-TB drugs
(amikacin, capreomycin, or kanamycin) in addition to
MDR) [8] are major concerns to TB control programs in
SSA. Finally, the association between RMP mono-
resistance and HIV infection has also been documented
[9]. Therefore, understanding the role of potential ‘drivers’
of DR-TB in SSA is important to guide intervention
policies and future drug resistance monitoring in the
region. We did a systematic review and meta-analysis of
published and unpublished studies to establish the variation
of DR-TB across SSA countries and its determinants.Methods
Data sources
We searched PubMed, EMBASE, and Cochrane for ori-
ginal publications from 2003 to 2013 without language
limitations. Search terms used included anti-TB drug re-
sistance, drug resistant tuberculosis, M/DR/XDR-TB, and
(isoniazid or rifampicin or ethambutol or streptomycin or
ofloxacin or fluoroquinolone or kanamycin or amikacin)
resistance for each country in SAA, excluding the Republic
of South Africa (RSA). Each term was searched separately
with a text string ending with the specific name of the
country. We excluded RSA because drivers of DR-TB in
this country are likely to be different and prevalence has
been reported to be substantially higher than the rest of
SSA countries [10]. We also searched bibliographies
of other reviews and citations of the original articles iden-
tified. Reviewers obtained unpublished DR-TB studies
through personal communication with experts and au-
thors of papers identified.
Study selection
We included surveys carried out both at national or sub-
national level reporting M/DR-TB prevalence or sufficient
data to calculate a prevalence of resistance to isoniazid
(INH), rifampicin (RMP), ethambutol (EMB), streptomycin
(SM), and/or MDR (INH and RMP). Conference pro-
ceedings, chapters of books, and correspondences were
excluded. Studies were considered of sufficient quality for
inclusion if participants were classified as new or previ-
ously treated based on the WHO definition [11], the study
covered a large geographical area (district, region, or en-
tire country), and recommended laboratory procedures
for culture and drug susceptibility testing (DST) were
followed [12]. Studies conducted in a single health unit
e.g. a referral hospital or a TB center, or those where
fewer than 50 participants had DST were excluded to
minimize bias of including non-representative samples of
the population. Where cluster sampling was used, adjust-
ment for the cluster design was a requirement for inclu-
sion in this review.
Two authors conducted the electronic searches in-
dependently; the last search was conducted in June
2014. Selection of articles was done by both reviewers
independently. Disagreements on articles to be in-
cluded were resolved by consensus among the two
authors.
Data extraction
We extracted data using pre-defined forms on: country
of the study; sampling method; description of the facil-
ities where the study was done; total number of patients
enrolled in the study as per treatment category; number
of patients with DST results; number of patients with a
positive result for resistance to INH, RMP, EMB, SM, or
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(if available). HIV prevalence at national level for each
country of interest was collected from the UNAIDS report
2013 [13]. Two authors extracted data independently
and any discrepancies in the data extracted were
resolved through discussions.Data synthesis and analysis
According to WHO, resistance among new cases is
defined as resistance to one or more anti-tuberculosis
drugs in patients that have never been treated for TB.
Resistance among previously treated TB patients, on the
other hand, is defined as resistance to one or more anti-
tuberculosis drugs in patients that have been treated for
TB. It can be transmitted from another patient with
DR-TB or acquired in patients diagnosed with pan-
sensitive TB who have started TB treatment and subse-
quently develop resistance to one or more of the drugs
used during the treatment. To generate data stratified for
the resistance among the new and previously treated TB
patients, we calculated pooled resistance prevalence along
with the 95% confidence interval through meta-analysis
using random effects models for MDR-TB and any
DR-TB to the first line drugs (INH, RMP, EMB, and SM).
We assessed the heterogeneity among reported prevalence
using the I2 statistic.
To explore the variation observed in the prevalence
estimates, we did a subgroup analysis by stratifying stud-
ies by predefined variables. In particular, we categorized
variables as follows: 1) by sub-region (Eastern sub-
region included Burundi, Ethiopia, Kenya, Rwanda,
Somalia, Uganda, and Tanzania; West Africa sub-region
included Benin, Burkina Faso, Cameroon, Equatorial
Guinea, Gambia, Ghana, Ivory Coast, and Nigeria; Southern
sub-region: Botswana, Zambia, Mozambique, Madagascar,
Swaziland, and Zambia; and Central Africa sub-region:
Central African Republic and Chad); 2) HIV prevalence at
a national level (countries with a prevalence of less than
5% compared to those with a prevalence of more than 5%
in the general population); 3) type of survey (national or
sub-national); 4) sampling method (random sampling or
cluster sampling); 5) sample size (studies of less than 100
patients or more than 100 patients); and HIV prevalence
among study participants (less than 40% compared to,
equal to or more than 40%).
We avoided use of acquired resistance for these cat-
egories of patients due to limitations of this definition
for acquired resistance as it does not put into consider-
ation possibilities of re-infection with resistant forms and
initial infection with resistant strains contributing to
treatment failure, since capacity to ascertain resistance
patterns prior to treatment initiation is rarely available
under routine settings.Results
We identified 725 citations through electronic data searches
and one completed study with unpublished data. Out
of these, 47 articles were selected for full text review,
of which 20 articles were excluded for various reasons
(Figure 1). Characteristics of the 27 articles included are
summarized in Table 1. Of these 27 studies, 19 (70%) re-
ported DR-TB data on both new and previously treated
patients. Seven studies reported resistance among new
cases only, while one study assessed DR-TB among the
previously treated. Sixteen (59%) studies reported HIV
testing, and HIV prevalence estimates at country level
were available for more than 90% of the studies. Thirteen
(48.1%) studies in total reported data at national level.
Compared to other regions, the eastern region contributed
the highest number of articles, five of which were from
national surveys.
DR-TB data was reported for a total of 15,462 sputum
smear-positive TB patients in the 27 articles included
from 2003 to 2013. Of these, 13,645 (88.4%) and 1,776
(11.6%) were new and previously treated patients, re-
spectively. All reported estimates for any resistance and
MDR-TB among new and previously treated patients are
presented separately by study in Figure 2. In Figure 3,
we then present pooled estimates for all resistance pat-
terns, including MDR-TB among new and previously
treated patients. Prevalence of any DR-TB and of MDR-TB
were higher among patients who had been previously
treated for TB (Figures 2 and 3). Overall, the pooled preva-
lence of any DR-TB among new and previously treated pa-
tients was 12.6% (95% CI 10.6-15.0%) and 27.2% (95% CI
21.4-33.8), respectively; while MDR-TB among the new
and previously treated patients was 1.5% (95% CI 1.0-2.3)
and 10.3% (95% CI 5.8-17.4), respectively. Summary esti-
mates for any DR-TB among new and previously treated
TB cases were highest for INH [7.8% (95% CI 6.5-9.4) and
23.1% (95% CI 15.9-32.2)] and lowest for EMB [1.9% (95%
CI 1.3-2.8) and 8.7% (95% CI 4.7-15.3)] (Figure 3). Resist-
ance to RMP in new cases, 2.0% (1.5-2.8) was also very
low (Figure 3).
Variation of DR-TB with key study characteristics
In Figures 4 and 5, we present the subgroup analyses for
the prevalence of any DR-TB and MDR-TB by study
characteristics. Overall, we observed larger variations in
the pooled estimates by subgroup with respect to any
DR-TB, compared to MDR estimates.
Regional variations
Prevalence of any DR-TB among new cases varied from
10.4% (95% CI 8.2- 13.1, n = 6) in the Southern region
to 17.0% (12.4-23.0, n = 2) in the Central region. Any
DR-TB among previously treated TB patients was highest
in East Africa with levels of 29.2% (95% CI 21.4-38.6,
Records identified through database 
searching  
(n =725)
Additional records identified through other 
sources  
(n = 1) 
Records after duplicates removed 
(n =537) 
Titles and abstracts screened  
(n =537)
Records excluded  
(n = 490) 
Full-text articles assessed for 
eligibility (n =47) 
Full-text articles 
excluded, with reasons 
(n = 20): 
Only one hospital 
participated, n=8  
Full text not available, 
n=5 
New and previously 
treated patients not 
presented separately, n=4 
Sample size too small, 
n=1 
Other reasons, n=2 
Studies included (n = 27) 
Studies included in quantitative 
synthesis (meta-analysis) (n =27) 
Figure 1 PRISMA flow chart.
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24.0% (95% CI 13.0-40.0, n = 6). MDR TB among new pa-
tients was lowest in Central Africa at 1.2% (95% CI 0.3-
5.5, n = 2) and highest in Western Africa, 2.3% (95% CI
1.0-4.8, n = 3), while MDR-TB among previously treated
was highest in Southern region, 11.7% (95% CI 5.0-25.0,
n = 6) and lowest in Eastern region, 9.6% (95% CI 4.7-
18.4, n = 9). We did not observe significant variations in
pooled estimates of any DR-TB or MDR-TB in the sub-
regions as shown by the overlap in the 95% CIs of our esti-
mates (Figures 4 and 5).
Country-level HIV prevalence
Analysis of any DR-TB among new cases in relation to
HIV infection rates (Figure 4) showed somewhat higher
resistance rates of 13.9% (95% CI 10.5-18.2, n = 12) in
countries where HIV prevalence was lower than 5%,
compared to countries where the prevalence was equal
to or higher than 5%, [11.2% (95% CI 8.7-14.2, n = 12)],
while DR-TB among the previously treated was almost the
same among settings with these different HIV prevalence
rates (26.1%, n = 8 vs 25.4%, n = 9). Primary MDR-TB insettings with less than 5% HIV prevalence was 1.9%
(95% CI 1.1-3.2 n = 9) as compared to 1.5% (95% CI 0.8-
2.8 n = 12) in settings where the HIV prevalence equal to
or higher than 5%. MDR-TB among previously treated
patients in countries with lower than 5% HIV prevalence
was 8.3% (95% CI 3.4-18.8, n = 11) compared to 11.0
(95% CI 5.8-19.9, n = 9) in countries with HIV preva-
lence of equal to or higher than 5%. However, differences
were small with largely overlapping 95% confidence
intervals.
TB/HIV co-infection
Where HIV testing was done as part of the survey
(Figure 4), we observe a higher prevalence of DR-TB
among new cases in studies where HIV was lower than
40% among the study participants [16.1% (95% CI 12.5-
20.6, n = 11)] as compared to 9.6% (95% CI 6.8-13.6, n = 4)
in studies where HIV prevalence among participants was
equal to or higher than 40%. Analysis of DR-TB among
previously treated cases in relation to these HIV co-
infection rates shows the same rates in these two settings,
those studies with lower than 40% HIV co-infection and
Table 1 Characteristics of studies included in the review of variation of M/DR-TB in SSA; 2003–2013
Author Study
year










Type of resistance tested
Minime-Lingoupou F et al. [21] 2009 Central African
Republic
Sub-national survey. TB
health facilities in Bangui
and Bimbo.
New patients 233 26 N/A LJ INH, RMP, SM, EMB
Asmamaw D. et al. [22] 2004 Ethiopia Sub-national survey.
Twenty-four TB health
facilities in Addis Ababa.
New patients 231 29.6 2.9 LJ INH, RMP, SM, EMB
Abdelhadi O. et al. [23] 2009-2010 Chad Sub-national survey.
Number of TB facilities
not provided.
New patients 135 25 3 LJ INH, RMP, SM, EMB
Yimer S.A. et al. [24] 2008 Ethiopia Sub-national survey.
Number of TB facilities in
Amhara not provided.
New patients 112 26.9 1.9 MGIT INH, RMP, SM, EMB
Urassa W. et al. [25] 2001-2004 Tanzania Sub-national survey. Five
TB health facilities in Dar
es Salaam.
New patients 887 53 5.7 LJ INH, RMP, SM, EMB
Ndungu PW. et al. [26] 2010 Kenya Sub-national survey. Five
TB health facilities in and
around Nairobi.
New patients 356 26.3 6.6 MGIT/LJ INH, RMP, SM, EMB
Matee M. et al. [27] 2005-2006 Tanzania Sub-national survey:
Thirty-seven TB facilities
of Temeke district.
New patients 226 N/A 5.8 LJ INH, RMP, SM, EMB





557 30.9 6.7 LJ INH, RMP, SM, EMB. Km
and O
Sanders M. et al. [29] 2008 Burundi Sub-national survey.




859 N/A 2.2 LJ INH, RMP, SM, EMB, PABA
Lukoye D. et al. (b) [30] 2009-2011 Uganda National survey. New and PT
patients
1537 30.7 7.3 LJ INH, RMP, SM, EMB, KM
and OFX
Umubyeyi A. N. et al. [31] 2004-2005 Rwanda National survey. New and PT
patients
701 N/A 3.3 LJ INH, RMP, SM, EMB
Irenious S. et al. [15] 2011 Somalia National survey. New and PT
patients
946 N/A N/A Hain INH, RMP only
Chonde TM et al. [32] 2006-2007 Tanzania National survey. New and PT
patients
1,167 N/A 5.8 LJ INH, RMP, SM, EMB
Tessema B. et al. [33] 2009 Ethiopia Sub-national survey. Five




260 25.4 1.7 LJ INH, RMP, SM, EMB, CPM,
OFX, AM, MFX, Amino
Salicylic Acid
Chanda M. et al. [34] 2006 Zambia Sub-national survey. Six























Table 1 Characteristics of studies included in the review of variation of M/DR-TB in SSA; 2003–2013 (Continued)
Nunes E.A. et al. [35] 2002-2003 Mozambique Sub-national survey.




111 N/A 9.8 LJ INH, RMP, SM, EMB
Nelson L.J. et al. [36] 2002 Botswana National survey. New and PT
patients
2,425 60 25.7 LJ INH, RMP, SM, EMB
Ramarokoto H. et al. [37] 2005-2007 Madagascar National survey. New and PT
patients
1,275 N/A 0.6 LJ INH, RMP, SM, EMB
Samo Gudo P. et al. [38] 2007-2008 Mozambique National survey. New and PT
patients
1,200 N/A 11.5 LJ INH, RMP, SM, EMB
Sanchez-Padilla E. et al. 2009 Swaziland National survey New and PT
patients
633 79.9 25.8 MGIT or
LJ
INH, RMP, SM, EMB
Edgbola R.A. et al. [39] 1999 Gambia National survey. New and PT
patients
225 N/A 2.1 LJ INH, RMP, SM, EMB








470 10.2 2.3 LJ INH, RMP, SM, EMB
Tudo G. et al. [41] 2004 Equatorial
Guinea
Sub-national survey.




236 13.5 3.6 LJ INH, RMP, SM, EMB
N'guesesan K. et al. [42] 2005 Ivory Coast National survey. New patients 320 N/A 4.9 LJ INH, RMP, SM, EMB
Sangare L. et al. [43] 2010 Bukina Furso National survey. New and PT
patients
416 28.7 1.3 LJ INH, RMP, SM, EMB
Ellis Awusu-Dabo et al. [44] 2001-2004 Ghana National survey. New and PT
patients
216 25.9 4.7 INH, RMP, SM, EMB,
Thiacetazone
Jurgen Noesk et al. [45] 2012 Cameroon Sub-national. Twenty-nine
TB health facilities in
Litoral region.
PT patients 233 26 N/A LJ INH, RMP, SM, EMB, Km
and GFX
Mbulo G.M.K. et al. Results of
the national drug resistance
survey in Zambia. (in
preparation)
2008 Zambia National survey. New and PT
patients
883 47.6 13.3 LJ INH, RMP, SM, EMB
Abbreviations: DST drug susceptibility testing, INH isoniazid, RMP rifampicin, EMB ethambutol, SM streptomycin, Km kanamycin, GFX gatifloxacin, CPM capreomycin, OFX ofloxacin, AM amikacin, N/A, not available,



















Figure 2 Forest plot of prevalence of any resistance and MDR among new and previously treated patients.
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http://www.biomedcentral.com/1471-2458/15/1/equal to or more than 40% of HIV co-infection, [29.1%,
95% CI = 24.3-34.4 n = 6 and 28.5% 95% CI 12.4-53.0
n = 3]. MDR among new cases in studies where TB/HIV
co-infection rates were lower than <40% was 1.8% (1.2-
2.7, n = 9); and 1.0% (0.2-5.7; n = 4); in studies with equalFigure 3 Pooled estimates for all resistance patterns among new and
estimate; INH, isoniazid; RMP, rifampicin; EMB, ethambutol; SM, streptomycito or higher than 40% TB/HIV co-infection. MDR-TB
among previously treated patients where TB/HIV co-
infection was lower than 40% among the participants was
10.6% (95% CI = 3.6-27.8, n = 8) and 14.6% (95% CI 4.4-
38.6, n = 3) where equal to or higher than 40% of thepreviously treated patients. Abbreviations: n, number of studies; ES,
n.
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Figure 4 Subgroup analysis: prevalence of any drug resistance. Abbreviations: n, number of studies; ES, estimate. Where data is missing,
it means that such a region did not have any study fitting that classification for inclusion in the analysis.
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was also not significant (Figure 5).
Study geographical coverage
Generally, articles reporting national surveys estimated
lower rates of any DR-TB among new cases 11.3% (95%
CI = 9.0-14.3, n = 13) as compared to sub-national re-
ports 14.2% (95% CI 10.6-18.6, n = 13). Any acquired
DR-TB was similar in the national (26.0%; 95% CI 18.1-
35.9, n = 11) and sub-national surveys (28%; 95% CI-
23.1-33.5, n = 7) (Figure 4). MDR estimates among new
cases were the same in both national and sub-national
studies at 1.6% (95% CI 0.9- 2.8, n = 11) and 1.6% (95% CI
1.0-2.5, n = 12) respectively, as were MDR rates among
the previously treated: 10.5% (95% CI 4.7-21.7, n = 13) ver-
sus 11.0% (95% CI 5.8-19.9, n = 8), respectively (Figure 5).
Sampling design
Studies that applied a cluster sampling design reported
lower rates of any DR-TB 9.7% (7.7-12.0; n = 6) in new
cases than studies where random sampling was used
13.8% (11.3-16.7; n = 20); DR-TB rates among previously
treated patients in these two study designs were 24.1%(14.1-38.0; n = 6) and 29.1% (22.3-36.9 n = 12) respect-
ively. Rates of MDR-TB followed a similar trend with
MDR-TB among the new patients in studies that used
cluster and random sampling designs reporting MDR-TB
rates of 1.0% (0.5-2.1; n = 6) and 1.8% (1.1-2.9; n = 17),
respectively. MDR-TB among the previously treated
category in studies that used cluster design was 9.9%
(3.7-24.3; n = 6), similar to that in studies where random
sampling was used [10.3% (5.1-19.9; n = 15)]. All the dif-
ferences in these measurements did not show statistical
significance (Figures 4 and 5).
Sample size
Studies with sample sizes of less than 100 participants
reported significantly higher rates of any DR-TB among
new cases, 22.4% (95% CI 10.8-40.0, n = 2) compared to
studies where 100 or more participants were recruited,
12.1% (95% CI 10.1-14.4, n = 24). Levels of DR-TB among
the previously treated were almost the same in both cat-
egories of sample size, 26.9% (95% CI 20.0-35.0, n = 13)
and 27.8% (95% CI 17.5-42.1, n = 5). For either category of
study size, MDR levels amongst new cases followed simi-
lar trends, significantly higher 6.7% (95% CI 2.5-16, n = 1)
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Figure 5 Subgroup analysis: prevalence of MDR-TB. Abbreviations: n, number of studies; ES, estimate, MDR- TB, Multi-drug resistant tuberculosis.
Where data is missing, it means that such a region did not have any study fitting that classification for inclusion in the analysis.
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1.4% (95% CI 1.0-2.1, n = 22) in studies with larger sample
sizes. Although slightly higher, levels of MDR-TB among
previously treated patients in studies with less than 100
participants, 11.8% (6.4%-20.8%, n = 14), this difference
was not statistically significant as compared to studies
with 100 participants or more, 8.5% (95% CI 3.1%-21.3%,
n = 7).
Publication bias
Finally, in Figure 6, we explored graphically the possibil-
ity of a publication bias. We did not observe an indica-
tion of such a bias in the studies included.
Discussion
In our study, we reviewed variations and risk factors of
DR-TB in SSA. We found that levels of any DR-TB and
MDR-TB are lower in SSA than reported globally [1]. In
particular, our results show MDR-TB prevalence esti-
mates as almost half as compared to the global average
reported by WHO for both new (1.5% vs 3.6%) and pre-
viously treated TB patients (10.3% vs 20.2%) [2]. These
consistent low levels occur in settings with high rates of
HIV, largely attributed, among other factors, to the late
introduction of RMP and limited availability of TB drugson the open market outside national TB programs [14]
in this region. According to the subgroup analyses, rates
of (M)DR-TB remain generally low regardless of the study
geographical coverage, sample size, HIV co-infection rates,
and sub-region where the study was conducted. This find-
ing happens at a time when more information on rates
and factors associated with of DR-TB in this region is
emerging, as more countries conduct surveys at national
and sub-national level [14], although data on DR-TB from
SSA is still limited [10]. The observed low levels of
(M)DR-TB may also reflect the functionality of TB control
programs in this region. Previous studies have shown that
countries where standardized regimens are available and
properly implemented, where quality drugs are regularly
supplied, and where systems are in place to ensure pa-
tients’ adherence are less likely to report high rates of
(M)DR-TB. From our findings, such explanation can be
supported by the high rates of MDR-TB from the Horn
of Africa included in our review, which could have re-
sulted from a break down in the public health system and
therefore in the functionality of the TB program due to
civil strife also observed elsewhere in the world [16,17].
Therefore, regional variations in MDR-TB rates might be
considered a proxy measure for functionality of national
TB programs which should alert national governments
Figure 6 Funnel plot exploring publication bias. The horizontal line represents the summary prevalence and guidelines are given to indicate
the 95% confidence interval for this estimate.
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of Mycobacterium tuberculosis (MTB) strains in transmis-
sibility and its potential to develop DR in this region
should not be ignored. As observed in some settings, par-
ticular MTB strains predominant in specific localities have
been associated with varying rates of MDR-TB [18].
Hence, more molecular studies are required to exam-
ine and explain possible associations of the predomin-
ant MTB strains with the observed prevalence of DR-TB
in SSA. Our findings seem to imply that transmission-
related factors such as late diagnosis, nosocomial spread,
and delay in initiation of second-line treatment as ob-
served in most settings of this region have not led to in-
crease in (M)DR-TB above the minimum WHO estimates.
However we observe higher rates of resistance to INH and
SM than other drugs in our analysis, also documented
earlier, attributed to the long history of INH and SM use
in management of TB and to the stepwise acquisition of
DR by MTB to these two drugs [19].
Lower levels of MDR-TB (1.5%) in settings with higher
HIV prevalence at population level, also observed where
HIV testing was included in the study design, could re-
sult from less participation rates of (M)DR-TB/HIV co-
infected patients in surveys due to either severe illness
or higher risk of death [8]. Where collection of individ-
ual HIV data was included in the study design, we found
higher rates of MDR-TB (25%) among previously treated
patients in studies where HIV prevalence was lower,possibly due to the same explanation and the possibil-
ity of suspected high MDR-TB rates in such populations.
We observed levels of any RMP resistance among new
cases (1.5%) in the analysis close to the reported preva-
lence of MDR-TB (2.0%). This finding is of significant
relevance in the current global and regional efforts to
accurately and timely diagnose MDR-TB with the scale-up
of molecular technology like GeneXpert MTB/RIF, pro-
viding quick results of RMP resistance as a proxy to
MDR-TB. In fact, in many SSA countries, access to cul-
ture and DST facilities is limited and molecular tech-
nologies might ease access to MDR-TB diagnosis and
reduce the time spent between diagnosis and initi-
ation of the patient on treatment. High levels of INH
and SM resistance found in our review, also documented
elsewhere, need to be monitored closely in relation to the
potential increase in treatment failure and relapse rates
with the current first-line drugs [20]. In light of the rec-
ommended roll-out of the RMP-through regimen by
WHO, especially in high HIV burden settings such as
SSA, TB programs need to ensure correct use of RMP in
drug -susceptible cases to avoid adding RMP resistance to
the already high levels of INH resistance, likely to lead to
high MDR-TB rates.
Finally, we observe higher rates of MDR-TB in smaller
studies as compared to larger ones possibly arising from
the difference in the core objectives of the studies. Stud-
ies with small sample sizes are usually done to explore
Lukoye et al. BMC Public Health 2015, 15: Page 11 of 13
http://www.biomedcentral.com/1471-2458/15/1/possibilities of high MDR-TB rates in specific populations.
Similarly, DR-TB rates in sub-national studies are higher
than in the national surveys since, in most cases, sample
sizes in such studies tend to be smaller, non-representative
of the population, and sometimes do not apply standard-
ized methodologies, although we aimed to exclude such
studies from our analysis. The lower (M)DR levels ob-
served in cluster surveys as compared to surveys where
random sampling was applied may have a similar explan-
ation. Cluster sampling designs are usually applied where
the study population is large and covering a wider geo-
graphical area for optimal use of resources without com-
promising the quality of the data. Consequently, lower
(M)DR rates in cluster surveys could have been a proxy to
the large sample sizes involved.
As demonstrated by the publication bias sub-analysis,
we observed no tendency from authors to publish papers
showing more or less resistance more frequently that
could distort our findings.
Limitations
Our review had some limitations. Of 44 countries in SSA
(excluding the Republic of South Africa), only 20 coun-
tries had done studies that fulfilled our inclusion criteria,
of which studies from five countries were not on a na-
tional scale. Many of the DR-TB surveys identified during
our searches were excluded because they took place at a
single health facility or had not stratified patients accord-
ing to their treatment history.
Although the association between HIV infection and
DR-TB is still controversial and deserves further explor-
ation, ten of the 27 studies analyzed did not include HIV
testing. It was, therefore, difficult to draw meaningful
conclusions. Similarly, we did not review data on na-
tional ART coverage due to challenges associated with
accessing accurate data to examine a possible relation-
ship between ART roll-out and levels of MDR-TB. Fi-
nally, results on second-line DST were not reported for
the majority of studies. This could be a reflection that
most countries in SSA had not initiated MDR-TB treat-
ment at the time of the study and the possibilities of
finding XDR-TB were limited, although this analysis
would be important especially in settings where some
fluoroquinolones (a cornerstone of second-line drug reg-
imens) are widely used for treatment of other bacterial
infections.
We excluded the republic of South Africa on the basis
of high levels of MDR-TB and XDR-TB rates in com-
parison to other countries of SSA [1,8], possibly fuelled
by high nosocomial transmission rates in the context of
very high rates of TB/HIV co-infection reported in this
country. We assumed that including such studies could
potentially skew our results towards higher DR-TB or
MDR-TB estimates.Conclusions
Our analysis showed low levels of MDR-TB in sub-
Saharan Africa compared to WHO estimates, with higher
resistance to INH and SM as reported elsewhere in the
world. There are no major variations in MDR-TB burden
by sub-region and evidence of association between MDR-
TB and HIV infection rates did not show statistical signifi-
cance. We attribute these low levels to the limited exist-
ence of anti-TB drugs outside the national programs, late
introduction of RMP in SSA, and wide use of fixed drug
combinations. Since these factors may apply to other set-
tings where rates of MDR-TB are higher, more studies are
required to explore other possible explanations for the
low levels of MDR-TB in SSA, such as the role of pre-
dominant MTB strains in generation and transmission
of DR-TB in this region
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